Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Corbus Pharmaceuticals Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc. has 6 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Corbus Pharmaceuticals Holdings, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Corbus Pharmaceuticals Holdings, Inc.. Customers appear here when Corbus Pharmaceuticals Holdings, Inc. names them, or when a company names Corbus Pharmaceuticals Holdings, Inc. as a supplier in its own annual report.
CRBP (Corbus Pharmaceuticals Holdings, Inc.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We are dependent on our licensing partner, CSPC, to manufacture antibody drug conjugates and we do not have control over their chemistry, manufacturing, and control strategy for CRB-701 to ensure successful development and supply of drug to commence clinical studies or support commercial demand.”
FILING10-K0001193125-26-098530cik 0001595097
“On May 31, 2023, we entered into Amendment No. 1 to the Open Market Sale Agreement originally dated August 6, 2020 (the "Open Market Sale Agreement") with Jefferies LLC ("Jefferies") pursuant to which Jefferies is serving as the sales agent.”
FILING10-K0001193125-26-098530cik 0001595097
“Pursuant to the terms of the license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), we are obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million for each compound we elect to develop based upon the achievement of specified development and regulatory milestones.”
FILING10-K0001193125-26-098530cik 0001595097
“Pursuant to the terms of the license agreement (the "UCSF License Agreement") with the Regents of the University of California, we are obligated to pay up to $150.8 million in remaining potential milestone payments based upon the achievement of specified development and regulatory milestones, excluding indication milestones for antibodies used for diagnostic products and services that will be an additional $50.0 thousand for each new indication.”
FILING10-K0001193125-26-098530cik 0001595097
“Interest expense relates primarily to interest expense on a loan from K2 HealthVentures LLC.”
FILING10-K0001193125-26-098530cik 0001595097
“We are a party to license agreements with Jenrin and The Regents pursuant to which we licensed exclusive worldwide rights to develop, manufacture and market drug candidates.”
FILING10-K0001193125-26-098530cik 0001595097
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 6.90 · gapped above the open, then crossed back over prior close. High/low 8.08 at 4:00 am ET, 6.42 at 11:30 am ET.